KPTI Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of -299.89% compared to Karyopharm Therapeutics, Inc.'s net margin of 16.99%. Karyopharm Therapeutics, Inc.'s return on equity of -- beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

Karyopharm Therapeutics, Inc. has a consensus price target of $15.33, signalling upside risk potential of 65.77%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 37.37%. Given that Karyopharm Therapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Karyopharm Therapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

Karyopharm Therapeutics, Inc. has a beta of 0.208, which suggesting that the stock is 79.163% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.

Karyopharm Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Karyopharm Therapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Karyopharm Therapeutics, Inc. quarterly revenues are $34.1M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Karyopharm Therapeutics, Inc.'s net income of -$102.2M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Karyopharm Therapeutics, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 147.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics, Inc. is 0.69x versus 11.96x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Baxter International, Inc. has a net margin of -299.89% compared to Karyopharm Therapeutics, Inc.'s net margin of -34.8%. Karyopharm Therapeutics, Inc.'s return on equity of -- beat Baxter International, Inc.'s return on equity of -12.97%.

Karyopharm Therapeutics, Inc. has a consensus price target of $15.33, signalling upside risk potential of 65.77%. On the other hand Baxter International, Inc. has an analysts' consensus of $21.63 which suggests that it could fall by -1.08%. Given that Karyopharm Therapeutics, Inc. has higher upside potential than Baxter International, Inc., analysts believe Karyopharm Therapeutics, Inc. is more attractive than Baxter International, Inc..

Karyopharm Therapeutics, Inc. has a beta of 0.208, which suggesting that the stock is 79.163% less volatile than S&P 500. In comparison Baxter International, Inc. has a beta of 0.593, suggesting its less volatile than the S&P 500 by 40.747%.

Karyopharm Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International, Inc. offers a yield of 2.38% to investors and pays a quarterly dividend of $0.01 per share. Karyopharm Therapeutics, Inc. pays -- of its earnings as a dividend. Baxter International, Inc. pays out 180.98% of its earnings as a dividend.

Karyopharm Therapeutics, Inc. quarterly revenues are $34.1M, which are smaller than Baxter International, Inc. quarterly revenues of $3B. Karyopharm Therapeutics, Inc.'s net income of -$102.2M is higher than Baxter International, Inc.'s net income of -$1B. Notably, Karyopharm Therapeutics, Inc.'s price-to-earnings ratio is -- while Baxter International, Inc.'s PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics, Inc. is 0.69x versus 1.00x for Baxter International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bruker Corp. has a net margin of -299.89% compared to Karyopharm Therapeutics, Inc.'s net margin of 2.99%. Karyopharm Therapeutics, Inc.'s return on equity of -- beat Bruker Corp.'s return on equity of -0.39%.

Karyopharm Therapeutics, Inc. has a consensus price target of $15.33, signalling upside risk potential of 65.77%. On the other hand Bruker Corp. has an analysts' consensus of $48.43 which suggests that it could grow by 21.8%. Given that Karyopharm Therapeutics, Inc. has higher upside potential than Bruker Corp., analysts believe Karyopharm Therapeutics, Inc. is more attractive than Bruker Corp..

Karyopharm Therapeutics, Inc. has a beta of 0.208, which suggesting that the stock is 79.163% less volatile than S&P 500. In comparison Bruker Corp. has a beta of 1.186, suggesting its more volatile than the S&P 500 by 18.621%.

Karyopharm Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker Corp. offers a yield of 0.5% to investors and pays a quarterly dividend of $0.05 per share. Karyopharm Therapeutics, Inc. pays -- of its earnings as a dividend. Bruker Corp. pays out 26.44% of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Karyopharm Therapeutics, Inc. quarterly revenues are $34.1M, which are smaller than Bruker Corp. quarterly revenues of $977.2M. Karyopharm Therapeutics, Inc.'s net income of -$102.2M is lower than Bruker Corp.'s net income of $29.2M. Notably, Karyopharm Therapeutics, Inc.'s price-to-earnings ratio is -- while Bruker Corp.'s PE ratio is 77.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics, Inc. is 0.69x versus 1.76x for Bruker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Catalyst Pharmaceuticals, Inc. has a net margin of -299.89% compared to Karyopharm Therapeutics, Inc.'s net margin of 35.57%. Karyopharm Therapeutics, Inc.'s return on equity of -- beat Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48%.

Karyopharm Therapeutics, Inc. has a consensus price target of $15.33, signalling upside risk potential of 65.77%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.57 which suggests that it could grow by 42.33%. Given that Karyopharm Therapeutics, Inc. has higher upside potential than Catalyst Pharmaceuticals, Inc., analysts believe Karyopharm Therapeutics, Inc. is more attractive than Catalyst Pharmaceuticals, Inc..

Karyopharm Therapeutics, Inc. has a beta of 0.208, which suggesting that the stock is 79.163% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.735, suggesting its less volatile than the S&P 500 by 26.455%.

Karyopharm Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Karyopharm Therapeutics, Inc. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Karyopharm Therapeutics, Inc. quarterly revenues are $34.1M, which are smaller than Catalyst Pharmaceuticals, Inc. quarterly revenues of $148.4M. Karyopharm Therapeutics, Inc.'s net income of -$102.2M is lower than Catalyst Pharmaceuticals, Inc.'s net income of $52.8M. Notably, Karyopharm Therapeutics, Inc.'s price-to-earnings ratio is -- while Catalyst Pharmaceuticals, Inc.'s PE ratio is 14.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics, Inc. is 0.69x versus 5.33x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.